Efficacy and safety of azithromycin versus lymecyline in the treatment of genital chlamydial infections in women
(1996) In Scandinavian Journal of Infectious Diseases 28(5). p.451-454- Abstract
- To compare the clinical and microbiological efficacy of azithromycin in curing chlamydial infections in women with that of lymecycline, and with a view of the possibility of minimizing the problem of compliance by means of single-dose administration, 146 women with culture-positive Chlamydia trachomatis infections were randomly assigned to treatment with a 1 g bolus dose of azithromycin or a 10-day course of lymecycline 300 mg twice daily. Clinical and microbiological evaluations were performed and adverse effects monitored at check-ups after 15-35 and 40-65 days. Of the 146 patients enrolled in the study, 120 were evaluable. At the second check-up, C. trachomatis was found to have been eradicated in all patients in both treatment groups.... (More)
- To compare the clinical and microbiological efficacy of azithromycin in curing chlamydial infections in women with that of lymecycline, and with a view of the possibility of minimizing the problem of compliance by means of single-dose administration, 146 women with culture-positive Chlamydia trachomatis infections were randomly assigned to treatment with a 1 g bolus dose of azithromycin or a 10-day course of lymecycline 300 mg twice daily. Clinical and microbiological evaluations were performed and adverse effects monitored at check-ups after 15-35 and 40-65 days. Of the 146 patients enrolled in the study, 120 were evaluable. At the second check-up, C. trachomatis was found to have been eradicated in all patients in both treatment groups. Of the 51 patients who had clinical signs and symptoms of genital infection at enrolment, 96% (22/23) of those in the azithromycin group were considered cured (n = 18) or improved (n = 4), as compared with 100% (28/28) of those considered cured (n = 22) or improved (n = 6) in the lymecycline group. Adverse events related, or possibly related, to treatment were reported by 16 (21.6%) of the lymecycline group, but by only 6 (8.3%) of the azithromycin group. The 2 drugs were comparable with regard to microbiological and clinical efficacy in the treatment of genital chlamydial infection in women. The markedly lower rate of side-effects associated with azithromycin may be a feature conducive to patient compliance. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1110979
- author
- Brihmer, Christina ; Mårdh, Per-Anders LU ; Kallings, Ingegerd ; Osser, Stellan LU ; Robech, Marcus ; Sikstrom, Bo and Wanger, Lena
- organization
- publishing date
- 1996
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scandinavian Journal of Infectious Diseases
- volume
- 28
- issue
- 5
- pages
- 451 - 454
- publisher
- Informa Healthcare
- external identifiers
-
- pmid:8953672
- scopus:0029844356
- ISSN
- 1651-1980
- DOI
- 10.3109/00365549609037938
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Department of Obstetrics and Gynaecology (Lund) (013018000), Pediatrics/Urology/Gynecology/Endocrinology (013240400)
- id
- daae5777-46a9-49fe-ae03-a99ac9f1b48c (old id 1110979)
- date added to LUP
- 2016-04-01 16:56:58
- date last changed
- 2022-01-28 23:17:28
@article{daae5777-46a9-49fe-ae03-a99ac9f1b48c,
abstract = {{To compare the clinical and microbiological efficacy of azithromycin in curing chlamydial infections in women with that of lymecycline, and with a view of the possibility of minimizing the problem of compliance by means of single-dose administration, 146 women with culture-positive Chlamydia trachomatis infections were randomly assigned to treatment with a 1 g bolus dose of azithromycin or a 10-day course of lymecycline 300 mg twice daily. Clinical and microbiological evaluations were performed and adverse effects monitored at check-ups after 15-35 and 40-65 days. Of the 146 patients enrolled in the study, 120 were evaluable. At the second check-up, C. trachomatis was found to have been eradicated in all patients in both treatment groups. Of the 51 patients who had clinical signs and symptoms of genital infection at enrolment, 96% (22/23) of those in the azithromycin group were considered cured (n = 18) or improved (n = 4), as compared with 100% (28/28) of those considered cured (n = 22) or improved (n = 6) in the lymecycline group. Adverse events related, or possibly related, to treatment were reported by 16 (21.6%) of the lymecycline group, but by only 6 (8.3%) of the azithromycin group. The 2 drugs were comparable with regard to microbiological and clinical efficacy in the treatment of genital chlamydial infection in women. The markedly lower rate of side-effects associated with azithromycin may be a feature conducive to patient compliance.}},
author = {{Brihmer, Christina and Mårdh, Per-Anders and Kallings, Ingegerd and Osser, Stellan and Robech, Marcus and Sikstrom, Bo and Wanger, Lena}},
issn = {{1651-1980}},
language = {{eng}},
number = {{5}},
pages = {{451--454}},
publisher = {{Informa Healthcare}},
series = {{Scandinavian Journal of Infectious Diseases}},
title = {{Efficacy and safety of azithromycin versus lymecyline in the treatment of genital chlamydial infections in women}},
url = {{http://dx.doi.org/10.3109/00365549609037938}},
doi = {{10.3109/00365549609037938}},
volume = {{28}},
year = {{1996}},
}